Benefit and Tolerability of IQP-AS-105 in Reducing Susceptibility to Upper Respiratory Tract Infections

Exclusion Criteria

• •acute / chronic upper airways disease
• •chronic cough of any origin
• •acute / chronic lower airways disease
• •any allergic reaction that may influence the study outcome (e.g. acute/chronic rhinitis)
• •history of nasal reconstructive surgery
• •presence of nasal ulcers or nasal polyps
• •severe nasal septum deviation or other condition that could cause nasal obstruction
• •congenital or acquired immunodeficiency disease (e.g. HIV infection)
• •severe organ or systemic diseases
• •body temperature above 37.5°C
• •suspected swine flu or influenza
• •vaccination against influenza or swine flu within 3 months prior to study start
• •stomach/gastrointestinal diseases
• •sleep disorder
• •psychiatric disorders
• •known sensitivity to the ingredients of the investigational product
• •intake of products that may influence the study outcome within the last 14 days prior to study start and during the study
• •analgesics , antibiotics or decongestant nose drops/spray, unless they are used as rescue medications
• •pregnancy or nursing
• •alcohol / drug abuse
• •simultaneous participation in another clinical trial or participation in a clinical trial within the last 30 days
• •insufficient compliance